Gastric cancer is cancer that starts anywhere inside the stomach or the stomach wall. Advanced gastric cancer can be locally advanced (has spread into the tissues around the stomach) or metastatic (has spread to at least one other part of the body such as the liver). Most gastric cancer cases are diagnosed at a late stage. Advanced cancers have poor prognosis and usually cannot be cured. However, it may be controlled, and symptoms can be relieved through treatment.
Nivolumab is a medicinal product that is currently licensed in the UK for the treatment of several types of advanced cancers such as melanoma, non-small cell lung cancer, and kidney cancer. It is a monoclonal antibody that acts by preventing the inhibition of T-cells (part of the body’s immune system that fight cancer) through binding to a protein called programmed cell death 1 (PD-1). Nivolumab is being developed to be used in addition to chemotherapy for the treatment of patients with advanced gastric cancer who have not had treatment previously. If licensed, nivolumab in combination with chemotherapy will offer an additional first-line treatment option for this patient group.
Brigatinib is a new treatment option being developed specifically for ALK-positive NSCLC. It acts by blocking the activity of some specific proteins encoded by the ALK gene, thereby reducing the growth of cancer cells. Brigatinib is taken orally once daily as a tablet and potentially has a broader range of resistance when compared other treatment options in its class. Brigatinib would be offered to patients with locally advanced or metastatic ALK-positive NSCLC, who have not received prior treatment. If licensed, brigatinib will offer an additional treatment option for this patient group.